SLFN11 and cancer: Validation of SLFN11 in a clinical setting (either in AS or in other, more common cancers in which patient inclusion is less challenging) may enable the design of a biomarker-driven basket study to investigate PARPi and TMZ combination therapy in cancer patients with SLFN11-positive tumors.